Do analysts recommend IPHA or SVA?

Innate Pharma presently has a consensus price target of $6.67, suggesting a potential upside of 205.81%. Given Innate Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Innate Pharma is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, IPHA or SVA?

Innate Pharma has higher earnings, but lower revenue than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 20.09 -$55.64M N/A N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is IPHA or SVA more profitable?

Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Sinovac Biotech N/A N/A N/A

Does the media refer more to IPHA or SVA?

In the previous week, Innate Pharma had 21 more articles in the media than Sinovac Biotech. MarketBeat recorded 23 mentions for Innate Pharma and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat Innate Pharma's score of 0.61 indicating that Sinovac Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ALLO or IPHA?

Innate Pharma has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 35,377.88 -$190.89M -$0.77 N/A Innate Pharma $10.19M 20.09 -$55.64M N/A N/A

Is ALLO or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -50.04% -36.74% Innate Pharma N/A N/A N/A

Does the media prefer ALLO or IPHA?

In the previous week, Innate Pharma had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 23 mentions for Innate Pharma and 14 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.80 beat Innate Pharma's score of 0.61 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IPHA or MDXG?

MiMedx Group has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 20.09 -$55.64M N/A N/A MiMedx Group $418.63M 1.49 $48.58M $0.04 106.75

Which has preferable valuation and earnings, IPHA or ALT?

Innate Pharma has higher revenue and earnings than Altimmune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 20.09 -$55.64M N/A N/A Altimmune $40K 14,293.55 -$88.09M -$0.93 N/A

Does the media favor IPHA or ALT?

In the previous week, Innate Pharma had 11 more articles in the media than Altimmune. MarketBeat recorded 23 mentions for Innate Pharma and 12 mentions for Altimmune. Innate Pharma's average media sentiment score of 0.61 beat Altimmune's score of 0.24 indicating that Innate Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, NVCT or IPHA?

Nuvectis Pharma has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Innate Pharma $10.19M 20.09 -$55.64M N/A N/A

Is NVCT or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Innate Pharma N/A N/A N/A

Does the media refer more to NVCT or IPHA?

In the previous week, Innate Pharma had 19 more articles in the media than Nuvectis Pharma. MarketBeat recorded 23 mentions for Innate Pharma and 4 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.89 beat Innate Pharma's score of 0.61 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Innate Pharma (IPHA) Competitors

$2.18 -0.36 (-14.17%)

Closing price 04:00 PM Eastern

Extended Trading

$2.16 -0.02 (-1.01%)

As of 07:55 PM Eastern

Compare

IPHA vs. SVA, ALLO, MDXG, ALT, and NVCT

Should you buy Innate Pharma stock or one of its competitors? Innate Pharma's main competitors and comparable companies include Sinovac Biotech (SVA), Allogene Therapeutics (ALLO), MiMedx Group (MDXG), Altimmune (ALT), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Innate Pharma compare to Sinovac Biotech?

Innate Pharma (NASDAQ:IPHA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Innate Pharma has higher earnings, but lower revenue than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	20.09	-$55.64M	N/A	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

In the previous week, Innate Pharma had 21 more articles in the media than Sinovac Biotech. MarketBeat recorded 23 mentions for Innate Pharma and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat Innate Pharma's score of 0.61 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innate Pharma has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Innate Pharma presently has a consensus price target of $6.67, suggesting a potential upside of 205.81%. Given Innate Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Innate Pharma is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Sinovac Biotech	N/A	N/A	N/A

Summary

Innate Pharma beats Sinovac Biotech on 8 of the 11 factors compared between the two stocks.

How does Innate Pharma compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Allogene Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Innate Pharma's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Innate Pharma	N/A	N/A	N/A

Allogene Therapeutics currently has a consensus price target of $8.52, indicating a potential upside of 315.72%. Innate Pharma has a consensus price target of $6.67, indicating a potential upside of 205.81%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innate Pharma has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	35,377.88	-$190.89M	-$0.77	N/A
Innate Pharma	$10.19M	20.09	-$55.64M	N/A	N/A

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Innate Pharma had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 23 mentions for Innate Pharma and 14 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.80 beat Innate Pharma's score of 0.61 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Allogene Therapeutics beats Innate Pharma on 8 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to MiMedx Group?

Innate Pharma (NASDAQ:IPHA) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

MiMedx Group has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	20.09	-$55.64M	N/A	N/A
MiMedx Group	$418.63M	1.49	$48.58M	$0.04	106.75

Innate Pharma has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Innate Pharma presently has a consensus target price of $6.67, suggesting a potential upside of 205.81%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 99.06%. Given Innate Pharma's higher possible upside, equities analysts clearly believe Innate Pharma is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 1.76% compared to Innate Pharma's net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
MiMedx Group	1.76%	12.09%	9.22%

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Innate Pharma had 22 more articles in the media than MiMedx Group. MarketBeat recorded 23 mentions for Innate Pharma and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.89 beat Innate Pharma's score of 0.61 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Innate Pharma	Positive
MiMedx Group	Very Positive

Summary

MiMedx Group beats Innate Pharma on 10 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Altimmune?

Innate Pharma (NASDAQ:IPHA) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Innate Pharma presently has a consensus price target of $6.67, suggesting a potential upside of 205.81%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 387.53%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Innate Pharma had 11 more articles in the media than Altimmune. MarketBeat recorded 23 mentions for Innate Pharma and 12 mentions for Altimmune. Innate Pharma's average media sentiment score of 0.61 beat Altimmune's score of 0.24 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innate Pharma has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Innate Pharma's return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Altimmune	-214,860.98%	-31.41%	-26.96%

Innate Pharma has higher revenue and earnings than Altimmune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	20.09	-$55.64M	N/A	N/A
Altimmune	$40K	14,293.55	-$88.09M	-$0.93	N/A

Innate Pharma has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Summary

Innate Pharma beats Altimmune on 9 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Nuvectis Pharma has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Innate Pharma	$10.19M	20.09	-$55.64M	N/A	N/A

Nuvectis Pharma presently has a consensus target price of $35.00, suggesting a potential upside of 84.60%. Innate Pharma has a consensus target price of $6.67, suggesting a potential upside of 205.81%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Innate Pharma had 19 more articles in the media than Nuvectis Pharma. MarketBeat recorded 23 mentions for Innate Pharma and 4 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.89 beat Innate Pharma's score of 0.61 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Innate Pharma's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Innate Pharma	N/A	N/A	N/A

Summary

Innate Pharma beats Nuvectis Pharma on 9 of the 12 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$238.09M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	N/A	10.67	269.06	25.28
Price / Sales	20.09	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-8.38	16.78	12.91	6.24
Net Income	-$55.64M	-$13.32M	$3.45B	$347.60M
7 Day Performance	26.01%	1.74%	1.12%	1.07%
1 Month Performance	21.79%	1.60%	1.79%	1.03%
1 Year Performance	N/A	56.43%	67.69%	20.77%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	3.6118 of 5 stars	$2.18 -14.2%	$6.67 +205.8%	+14.9%	$238.09M	$10.19M	N/A	220	News Coverage Analyst Upgrade Analyst Revision Gap Down
SVA Sinovac Biotech	0.9343 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	News Coverage High Trading Volume
ALLO Allogene Therapeutics	2.108 of 5 stars	$1.90 +3.3%	$8.52 +348.5%	+90.4%	$635.08M	$20K	N/A	310	News Coverage Earnings Report Analyst Downgrade
MDXG MiMedx Group	3.3497 of 5 stars	$4.27 flat	$8.50 +99.1%	-42.2%	$622.40M	$418.63M	106.78	870
ALT Altimmune	2.4565 of 5 stars	$3.07 +2.3%	$15.71 +411.9%	-23.0%	$583.42M	$40K	N/A	50	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. SVA, ALLO, MDXG, ALT, and NVCT

How does Innate Pharma compare to Sinovac Biotech?

Summary

How does Innate Pharma compare to Allogene Therapeutics?

Summary

How does Innate Pharma compare to MiMedx Group?

Summary

How does Innate Pharma compare to Altimmune?

Summary

How does Innate Pharma compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. SVA, ALLO, MDXG, ALT, and NVCT

How does Innate Pharma compare to Sinovac Biotech?

Which has higher valuation & earnings, IPHA or SVA?

Does the media refer more to IPHA or SVA?

Which has more risk & volatility, IPHA or SVA?

Do analysts recommend IPHA or SVA?

Do insiders & institutionals hold more shares of IPHA or SVA?

Is IPHA or SVA more profitable?

Summary

How does Innate Pharma compare to Allogene Therapeutics?

Which has more risk and volatility, ALLO or IPHA?

Is ALLO or IPHA more profitable?

Do analysts prefer ALLO or IPHA?

Which has higher valuation & earnings, ALLO or IPHA?

Do institutionals & insiders hold more shares of ALLO or IPHA?

Does the media prefer ALLO or IPHA?

Summary

How does Innate Pharma compare to MiMedx Group?

Which has higher valuation and earnings, IPHA or MDXG?

Which has more risk and volatility, IPHA or MDXG?

Do analysts rate IPHA or MDXG?

Is IPHA or MDXG more profitable?

Do insiders & institutionals have more ownership in IPHA or MDXG?

Does the media favor IPHA or MDXG?

Summary

How does Innate Pharma compare to Altimmune?

Do analysts prefer IPHA or ALT?

Do institutionals & insiders have more ownership in IPHA or ALT?

Does the media favor IPHA or ALT?

Is IPHA or ALT more profitable?

Which has preferable valuation and earnings, IPHA or ALT?

Which has more volatility and risk, IPHA or ALT?

Summary

How does Innate Pharma compare to Nuvectis Pharma?

Which has higher valuation and earnings, NVCT or IPHA?

Do analysts prefer NVCT or IPHA?

Does the media refer more to NVCT or IPHA?

Which has more volatility & risk, NVCT or IPHA?

Do institutionals and insiders believe in NVCT or IPHA?

Is NVCT or IPHA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools